Riverview Trust Co purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel reports. The fund purchased 1,830 shares of the biopharmaceutical company’s stock, valued at approximately $114,000.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after purchasing an additional 31,335,030 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Gilead Sciences by 5,733.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 28,491,386 shares during the period. Capital Research Global Investors raised its position in shares of Gilead Sciences by 22.5% during the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock worth $5,393,502,000 after purchasing an additional 12,818,301 shares during the period. BlackRock Inc. raised its position in shares of Gilead Sciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock worth $6,516,839,000 after purchasing an additional 2,195,948 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of Gilead Sciences by 21.1% during the third quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock worth $790,738,000 after purchasing an additional 1,786,881 shares during the period. 78.23% of the stock is currently owned by hedge funds and other institutional investors.
GILD stock opened at $64.79 on Friday. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $80.90. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.29. The firm has a market capitalization of $82.69 billion, a PE ratio of 10.53, a price-to-earnings-growth ratio of 4.08 and a beta of 1.16.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 6.23 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 annualized dividend and a dividend yield of 3.89%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is presently 37.07%.
In related news, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.16% of the company’s stock.
A number of research firms recently commented on GILD. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, November 21st. Guggenheim began coverage on Gilead Sciences in a research report on Monday, December 17th. They issued a “buy” rating and a $86.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $92.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 19th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $85.00 to $86.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 19th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Hold” and an average target price of $82.56.
ILLEGAL ACTIVITY NOTICE: “Riverview Trust Co Purchases Shares of 1,830 Gilead Sciences, Inc. (GILD)” was first posted by Highlight Press and is the sole property of of Highlight Press. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://highlightpress.com/2019/03/15/riverview-trust-co-purchases-shares-of-1830-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How are institutional investors different from individual investors?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.